HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: Empiric Treatment for Acute HIV in the ED [Phase 4]
Phase 4 clinical trial update evaluating empiric treatment for acute HIV infection in the emergency department.
-
EMA approval · 2023-04-25EMA Authorised: Stocrin (efavirenz) — Merck Sharp & Dohme B.V.
EFAVIRENZ (Stocrin) has been authorised by the EMA for HIV infections.
-
FDA approval · 2023-04-25FDA Approved: ABACAVIR SULFATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Abacavir Sulfate submitted by Mylan Pharmaceuticals Inc.
-
FDA approval · 2023-04-25FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Tenofovir disoproxil fumarate by Aurobindo Pharma Limited. This approval relates to a generic pr…
-
CLINICAL_TRIALS withdrawal · 2023-04-25Clinical Trial Update: To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults [Phase 3]
Phase 3 trial investigating UB-421 monotherapy for HIV-1 infection has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection [Phase 3]
Phase 3 trial update for UB-421 combined with an optimized background regimen in patients with multi-drug resistant HIV-1 infection; study s…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients [Phase 2]
Phase 2 clinical trial update investigating UB-421 with an optimized background regimen in patients with multi-drug resistant HIV-1 infectio…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: Suppression of HIV 1 RNA in People Living With HIV [NA]
Clinical trial update reporting suppression of HIV-1 RNA in people living with HIV; study completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk [Phase 2]
Phase 2 trial evaluating IL-1β inhibition to reduce inflammation and cardiovascular risk in people with HIV and cardiovascular disease; resu…
-
FDA approval · 2023-04-19FDA Approved: LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for a generic lamivudine and zidovudine tablet product, a fixed-dose combinati…
-
FDA approval · 2023-04-18FDA Approved: ABACAVIR AND LAMIVUDINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Abacavir/lamivudine from Aurobindo Pharma Limited, enabling the marketing of this generic fi…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa [Phase 2]
Phase 2 trial examining a heterologous prime/boost HIV vaccine regimen (Ad26.Mos4.HIV and aluminum phosphate-adjuvanted gp140) in women in S…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Linking Infectious and Narcology Care-Part II [Phase 4]
Phase 4 clinical trial assessing integration of infectious disease and narcology care for people with HIV infection and drug use; completed …
-
FDA approval · 2023-04-14FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2023-04-06FDA Approved: EFAVIRENZ — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' supplemental application for efavirenz (generic) as an antiretroviral for HIV-1 infection.
-
FDA approval · 2023-04-05FDA Approved: LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Lamivudine and Zidovudine from Exelan Pharmaceuticals, confirming continued availability of this…
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection: [Phase 2]
A Phase 2 clinical trial evaluating whether BCG vaccination affects latent HIV-1 reservoir size in treated HIV-1 infection.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients [Phase 2]
Phase 2 clinical trial investigating the effects of cannabidiol (CBD) on autophagy and inflammation gene activation in virologically control…
-
FDA approval · 2023-03-31FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approves a supplemental application for Prezista (darunavir) from Janssen Products LP.
-
FDA approval · 2023-03-31FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for PREZISTA (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2023-03-31FDA Approved: NEVIRAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Nevirapine by Aurobindo Pharma Limited. This action records a supplementary approval for a g…
-
FDA approval · 2023-03-31FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for Prezcobix (darunavir ethanolate and cobicistat) submitted by Janssen Products, LP.
-
FDA approval · 2023-03-31FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide), a fixed-dose HIV-…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults [Phase 1, Phase 2]
Phase 1/2 safety, pharmacokinetics, and pharmacodynamics study of ABX464 in HIV-1 seronegative and seropositive adults completed with posted…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients [Phase 2]
Phase 2 trial update on the safety and efficacy of T8 for chronic abnormal immune activation in HIV/AIDS patients.